CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement
healthbook TIMES Oncology Hematology · 2019
DOI: 10.36000/hbt.oh.2019.01.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift healthbook TIMES Oncology Hematology, 2019. Verfasst von Alexander Ring und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting. Chimeric antigen receptor (CAR) T cells are genetically engineered using autologous patient lymphocytes and have shown very promising results in the treatment of relapsed and refractory cases of DLBCL.
Methods
A 64-year-old male patient with refractory DLBCL and central nervous system (CNS) involvement after 9 lines of therapy was treated with CD19-specific CAR T cell therapy at the Department of medical oncology and hematology at the University Hospital of Zurich and followed-up for 10 weeks.
Results
Autologous lymphocytes were successfully harvested and transfected/expanded for CAR T cell production. Conditioning chemotherapy and CAR T infusion was well tolerated. Post-infusion side effects were mild (cytokine release syndrome [CRS] grade 1−2), with limited signs of neurotoxicity. Ten weeks after CAR T cell therapy, an excellent response could be documented via PET-CT. The CNS lesion disappeared as assessed via cranial MRI.
Conclusion
CD19-targeted CAR T cell therapy is a revolutionary treatment option for heavily pre-treated R/R DLBCL even in the setting of CNS involvement.
Zitieren
APA
Ring, A., & Müller, A. M. (2019). CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement. healthbook TIMES Oncology Hematology. https://doi.org/10.36000/hbt.oh.2019.01.005
Vancouver
Ring A, Müller AM. CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement. healthbook TIMES Oncology Hematology. 2019. doi:10.36000/hbt.oh.2019.01.005
BibTeX
@article{Ring2019,
author = {Ring, Alexander and Müller, Antonia Maria},
title = {CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement},
journal = {healthbook TIMES Oncology Hematology},
year = {2019},
doi = {10.36000/hbt.oh.2019.01.005}
}
EUVIMED